Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

Jeet Gandhi, Jianling Zhang, Yang Xie et al. · 2009

Read Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines by Jeet Gandhi, Jianling Zhang, Yang Xie et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004576.txt.

Description

Changes across a growth signaling pathway decide which lung cancers answer a key drug class, report Jeet Gandhi, Jianling Zhang, Yang Xie, and co-authors in PLOS ONE in 2009. The pathway centers on EGFR, a receptor that drives cell growth. Its deregulation is common in non-small cell lung cancers. That led to tyrosine kinase inhibitors, drugs that are highly effective in a subset of patients.

The team studied lung cancer cell lines, cataloging mutations and copy number gains in EGFR and alterations in other genes of its pathway. They related those patterns to sensitivity to the inhibitors. Knowing which changes predict a response helps oncologists pick the patients a drug will help, instead of treating everyone and hoping.

Catalog record

CREATORJeet Gandhi, Jianling Zhang, Yang Xie et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004576

Browse the full library · About the Tower of Babel